Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
2018
146 citations
Journal Article
gold Open Access
Field-Weighted Citation Impact:
6.31
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors | Researchclopedia
Hussein Tawbi
Joseph Rubino
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Thomas S. Rush
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Da Zhang
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Nathan R. Miselis
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Ahmed A. Samatar
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Patrick Chun
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Eric H. Rubin
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
James E. Schiller
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Brian J. Long
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Priya Dayananth
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Donna Carr
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Paul T. Kirschmeier
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
W. Robert Bishop
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Yongqi Deng
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Alan Cooper
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Gerald W. Shipps
·
Merck & Co., Inc., Rahway, NJ, USA (United States)
Blanca Homet Moreno
Lídia Robert
Antoni Ribas
Keith T. Flaherty
·
Massachusetts General Hospital